PSI-IBD - Parelsnoer Inflammatory Bowel Diseases

National biobank to facilitate clinically relevant multi-omics research in patients with IBD. Cohort

National biobank to facilitate clinically relevant multi-omics research in patients with IBD.

Inflammatory Bowel Diseases (IBD) are diseases characterized by inflammation of the gastrointestinal tract, including Crohn’s disease and ulcerative colitis.

Affecting approximately 100.000 persons in the Netherlands alone, the prevalence of IBD is rising. Its cause is multifactorial, involving a complex interplay between host genetics, environmental factors including the diet and dysregulated immune responses towards the gut microbiome.

PSI-IBD aims to:

gain further knowledge of the complex etiology of development and course of IBD;
search for predictors of treatment response;
use multi-omics data research of large groups of patients and translate its findings to personalized treatment of individual patients.

Patients are eligible for participation if:
- they are ≥18 years old;
- they have a confirmed IBD diagnosis according to the applicable guidelines at time of diagnosis;
- they are capable of will and knowledgeable in the Dutch language.
Patients with primary sclerosing cholangitis.
Please visit the UMCG Research Data Catalogue for more detailed information on our data and samples.

The following data is included:
- clinical data, amongst others general and IBD-specific medical and surgical history, disease characteristics (Montreal classification), extra-intestinal manifestations. medication use, endoscopy results, laboratory and radiology findings, disease activity scores;
- questionnaires, including the Groningen IBD Environmental Questionnaire (GIEQ), Groningen IBD Nutritional Questionnaire (GINQ), Food Frequency Questionnaires (FFQ);
- biomaterials: Serum, EDTA plasma for extraction of genome data, PAXgene blood tubes for mRNA analysis, Faeces for extraction of microbiome data, tissue (gastrointestinal biopsies and surgical tissue).
Within the UMCG:
Outside of the UMCG:
- Initiative on Crohn and Colitis (ICC) | Inflammatory Bowel Disease (IBD) (icc-ibd.com)
- Multicenter klinische biobanken | Health-RI
Please visit Centrum voor Chronische Darmziekten for more information about patient participation (in Dutch).
Publications PSI-IBD (University of Groningen)

Relevance

How PSI-IBD benefits to society

IBD is one of the immune mediated inflammatory diseases (IMID) that is showing a rising incidence worldwide. Therefore, exploration of (modifiable) factors involved in disease development as well as its course is crucial for future preventative strategies. Also, research focused on prediction of medication efficacy instead of the current trial-and-error treatment strategy, will potentially lead to better disease management (i.e. shorter time to remission) and decrease in health care costs.